Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02205554 · ClinicalTrials.gov registry record · Phase 1
Omnitram Pharmacokinetic Study In Healthy Volunteers
A Phase 1 study, sponsored by Syntrix Biosystems.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT02205554 is a Phase 1 study that has completed, run by Syntrix Biosystems. The registered enrollment target is 43 participants.
The verdict
NCT02205554, a Phase 1 study, has completed, sponsored by Syntrix Biosystems.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety, pharmacokinetic properties (the absorption, distribution and excretion), and analgesic activity of Omnitram (10 mg tablets), Tramadol (Ultram, 50 mg tablet) following oral administration of 9 doses healthy subjects.
Interventions
- DRUG Placebo
- DRUG Tramadol
- DRUG Omnitram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02205554
The ClinicalTrials.gov registry entry for NCT02205554 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syntrix Biosystems, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02205554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02205554 about?
NCT02205554 is a clinical study titled "Omnitram Pharmacokinetic Study In Healthy Volunteers". The purpose of this study is to compare the safety, pharmacokinetic properties (the absorption, distribution and excretion), and analgesic activity of Omnitram (10 mg tablets), Tramadol (Ultram, 50 mg tablet) following oral administration of 9 doses healthy subjects.
What is the current status of trial NCT02205554?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2014-08. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02205554?
The interventions under investigation include: Placebo (DRUG), Tramadol (DRUG), Omnitram (DRUG).
Who is sponsoring clinical trial NCT02205554?
This trial is sponsored by Syntrix Biosystems, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.